KOVERA LABS · CLIENT RECORD·SNAPSHOT 2026-08-02
Renova Peptides: 22 Kovera certificates.
The lab's record shows 22 certificates printed for Renova Peptides, analysed between 10 Apr 2026 and 13 May 2026, covering 11 products. Median HPLC purity is 99.88%. Kovera graded 22 as a pass and 0 as a fail.
22
certificates
99.88%
median purity
11
products
0
lab verdict: fail
0
failure rules met
What the record shows
RETRIEVED 2 AUGUST 2026None of the 22 certificates meets our failure rules: no lab fail, no unconfirmed identity, no purity under 95% and no content under 90% of the label. 12 measured more than 110% of the label, which Kovera does not grade as a fail.
A certificate covers the sample the client sent, and the client decides which results go public. The figures are as published on 2 August 2026; check the lab's verify page for the current version before you rely on one.
Products tested
11 AS PRINTEDRetatrutide · 6Tirzepatide · 4Tesamorelin · 3MOTS-c · 2BPC-157/TB-500 · 1CJC-1295 (No DAC)/Ipamorelin · 1GHK-Cu · 1Glow · 1Klow · 1NAD+ · 1PT-141 · 1
Every certificate
NEWEST FIRST · 22 ROWS| Report | Product | Lot | Purity | % of label | Analysed | Result | Check |
|---|---|---|---|---|---|---|---|
| KVR-2026-F5D17E-S124 | Tirzepatide | TR300626 | 99.956% | 107.5%32.25 of 30 mg | 13 May 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-84E44E-S118 | Klow | KL800526 | 99.908% | 111.4%89.11 of 80 mg | 13 May 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-4A3B51-S121 | PT-141 | PT100526 | 99.865% | 110.0%11 of 10 mg | 13 May 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-EE59DB-S98 | NAD+ | NAD5000526 | 99.885% | 107.0%534.78 of 500 mg | 7 May 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-E3C175-S104 | Tesamorelin | TS100526 | 99.939% | 113.1%11.31 of 10 mg | 7 May 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-C92C0E-S107 | MOTS-c | MTS400526 | 99.948% | 110.6%44.23 of 40 mg | 7 May 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-B61789-S101 | Tesamorelin | TS200526 | 99.888% | 112.2%22.45 of 20 mg | 7 May 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-DA084C-S73 | Tirzepatide | TZ300326 | 99.92% | 111.4%33.41 of 30 mg | 15 Apr 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-A3E4B4-S82 | MOTS-c | MTS100326 | 99.863% | 110.4%11.04 of 10 mg | 15 Apr 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-A36A5F-S69 | Tirzepatide | TZ100326 | 99.881% | 105.3%10.53 of 10 mg | 15 Apr 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-8F88BE-S58 | BPC-157/TB-500 | BT200426 | 99.649% | 112.2%22.44 of 20 mg | 15 Apr 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-7FC973-S64 | CJC-1295 (No DAC)/Ipamorelin | CJIP0326 | 99.774% | 111.5%11.15 of 10 mg | 15 Apr 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-7CF218-S61 | GHK-Cu | GK1000426 | 99.862% | 108.3%108.35 of 100 mg | 15 Apr 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-5CF3DD-S76 | Tirzepatide | TZ600326 | 99.901% | 105.2%63.12 of 60 mg | 15 Apr 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-51E157-S79 | Glow | Glow700326 | 99.763% | 105.5%73.87 of 70 mg | 15 Apr 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-4A9814-S67 | Tesamorelin | TS100326 | 99.922% | 111.0%11.1 of 10 mg | 15 Apr 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-E1FE69-S55 | Retatrutide | RT600326 | 99.876% | 105.5%63.29 of 60 mg | 13 Apr 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-D6DE97-S46 | Retatrutide | RT200326 | 99.832% | 110.9%22.18 of 20 mg | 13 Apr 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-D36F55-S52 | Retatrutide | RT500326 | 99.888% | 106.2%53.1 of 50 mg | 13 Apr 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-CD3D3A-S43 | Retatrutide | RT100326 | 99.808% | 117.8%11.78 of 10 mg | 13 Apr 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-C3824D-S49 | Retatrutide | RT300326 | 99.857% | 113.1%33.92 of 30 mg | 13 Apr 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-1A2E79 | Retatrutide | RT100326 | 99.876% | 105.3%10.53 of 10 mg | 10 Apr 2026 | PASS | Kovera ↗our verifier → |